熱門資訊> 正文

Talaris Therapeutics GAAP每股收益为-0.86美元

2025-03-13 21:19

Talaris Therapeutics press release (NASDAQ:TRML): Q4 GAAP EPS of -$0.86.
Cash, cash equivalents and investments were $294.9 million as of December 31, 2024, as compared to $203.0 million as of December 31, 2023.

More on Talaris Therapeutics

Tourmaline Bio rises as Wedbush initiates with Outperform on lead asset
Seeking Alpha’s Quant Rating on Talaris Therapeutics
Historical earnings data for Talaris Therapeutics
Financial information for Talaris Therapeutics

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。